https://www.taxtmi.com/news?id=68444 NEXIPOX PLUS is a reformulated live attenuated varicella vaccine using a 2X trehalose stabiliser to enhance viral stability, preserve potency, reduce antigen crystallisation and lower allergic-reaction risk. Clinical data report 98% seroconversion after a two-dose schedule and a 35.4-fold geometric mean rise in antibody titres, with no serious adverse events causally linked to the vaccine and improved tolerability following removal of gelatin. The product is approved by the Drugs Controller General of India for use from 12 months of age and is protected by patents across 156 countries. en-us Sat, 24 Jan 2026 10:31:04 +0530 Sat, 24 Jan 2026 10:31:04 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=68444 NEXIPOX PLUS is a reformulated live attenuated varicella vaccine using a 2X trehalose stabiliser to enhance viral stability, preserve potency, reduce antigen crystallisation and lower allergic-reaction risk. Clinical data report 98% seroconversion after a two-dose schedule and a 35.4-fold geometric mean rise in antibody titres, with no serious adverse events causally linked to the vaccine and improved tolerability following removal of gelatin. The product is approved by the Drugs Controller General of India for use from 12 months of age and is protected by patents across 156 countries. News - Sat, 24 Jan 2026 10:31:04 +0530 https://www.taxtmi.com/news?id=68444